spironolactone has been researched along with angiotensinogen in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Barrett, JC; Eggena, P; Sambhi, MP; Thananopavarn, C; Tuck, M; Wiedeman, CE | 1 |
| Barthelmebs, M; De Jong, W; De Kloet, ER; Grima, M; Imbs, JL; Rahmouni, K; Sibug, RM | 1 |
| Ganten, D; Lal, A; Leenen, FH; Veinot, JP | 1 |
| Leenen, FH | 1 |
| Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yoneda, T; Zhu, A | 1 |
| Cavallari, LH; Dai, Y; Groo, VL; Patel, SR; Stamos, TD; Viana, MA | 1 |
| Beil, M; Chen, W; Dole, WP; Fu, F; Hu, CW; Jeng, AY; LaSala, D; Leung-Chu, J; Liang, G; Liu, J; Ménard, J; Rebello, S; Rigel, DF; Watson, C; Zhang, Y | 1 |
| Khan, SR; Peck, AB; Shimizu, N; Sunil, J; Tsuji, H; Uemura, H; Wang, W; Yoshimura, K | 1 |
| Cavallari, LH; El Rouby, NM; El-Wakeel, LM; Khorshid, H; Langaee, T; Sabri, NA; Sarhan, NM; Schaalan, MF; Shahin, MH; Solayman, MH | 1 |
1 trial(s) available for spironolactone and angiotensinogen
| Article | Year |
|---|---|
Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
Topics: Angiotensinogen; Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Double-Blind Method; Eplerenone; Haplorhini; Heart; Humans; Imidazoles; Kidney; Male; Placebos; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Spironolactone; Translational Research, Biomedical | 2014 |
8 other study(ies) available for spironolactone and angiotensinogen
| Article | Year |
|---|---|
A circulating renin activator in essential hypertension.
Topics: Angiotensin II; Angiotensinogen; Animals; Blood Pressure; Contraceptives, Oral; Diuretics; Enzyme Activation; Functional Laterality; Haplorhini; Humans; Hydrochlorothiazide; Hypertension; In Vitro Techniques; Kinetics; Renal Artery Obstruction; Renin; Sodium; Spironolactone | 1975 |
Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Topics: Angiotensinogen; Animals; Atrial Natriuretic Factor; Blood Pressure; Brain; Chlorides; Desoxycorticosterone; Diuresis; Hypertension; Injections, Intraventricular; Kidney; Male; Mineralocorticoid Receptor Antagonists; Potassium; Rats; Rats, Wistar; Receptors, Mineralocorticoid; RNA, Messenger; Sodium; Sodium Chloride, Dietary; Spironolactone; Time Factors; Transcription, Genetic | 2002 |
Prevention of cardiac remodeling after myocardial infarction in transgenic rats deficient in brain angiotensinogen.
Topics: Aldosterone; Angiotensinogen; Animals; Animals, Genetically Modified; Brain; Cell Size; Fibronectins; Fibrosis; Heart Ventricles; Immunohistochemistry; Laminin; Male; Myocardial Infarction; Myocytes, Cardiac; Organ Size; Radioimmunoassay; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Spironolactone; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2005 |
Brain mechanisms contributing to sympathetic hyperactivity and heart failure.
Topics: Angiotensinogen; Animals; Animals, Genetically Modified; Gene Transfer Techniques; Heart Failure; Infusions, Parenteral; Interleukin-10; Models, Cardiovascular; Models, Neurological; Myocardial Infarction; Norepinephrine; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; RNA, Antisense; RNA, Messenger; Spironolactone; Supraoptic Nucleus; Sympathetic Nervous System; Ventricular Remodeling | 2007 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomegaly; Endothelium, Vascular; Eplerenone; Fibrosis; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Spironolactone; Tetrazoles | 2007 |
Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensinogen; Black or African American; Cohort Studies; Diuretics; Female; Genotype; Heart Failure; Humans; Hyperkalemia; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Potassium; Receptors, Mineralocorticoid; Spironolactone; Statistics as Topic; White People | 2010 |
Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Angiotensinogen; Animals; Calcium Oxalate; Cell Line; Cytochrome P-450 CYP11B2; Disease Models, Animal; Enzyme Inhibitors; Ethylene Glycol; Gene Expression Profiling; Hyperoxaluria; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; NADPH Oxidases; Onium Compounds; Protein Phosphatase 2; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Receptors, Mineralocorticoid; Renin; Renin-Angiotensin System; RNA, Messenger; Spironolactone; Steroid 11-beta-Hydroxylase | 2016 |
Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure.
Topics: Adult; Aged; Angiotensinogen; Cytochrome P-450 CYP11B2; Egypt; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Potassium; Prognosis; Prospective Studies; Quality of Life; Renin-Angiotensin System; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Function, Left; Young Adult | 2020 |